[go: up one dir, main page]

EP2866830A4 - Agents anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 et anti-cxcr5 pour l'inhibition de l'inflammation - Google Patents

Agents anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 et anti-cxcr5 pour l'inhibition de l'inflammation

Info

Publication number
EP2866830A4
EP2866830A4 EP12880044.8A EP12880044A EP2866830A4 EP 2866830 A4 EP2866830 A4 EP 2866830A4 EP 12880044 A EP12880044 A EP 12880044A EP 2866830 A4 EP2866830 A4 EP 2866830A4
Authority
EP
European Patent Office
Prior art keywords
cxcl11
cxcl13
cxcl9
cxcr5
cxcl10
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12880044.8A
Other languages
German (de)
English (en)
Other versions
EP2866830A1 (fr
Inventor
James W Lillard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JYANT TECHNOLOGIES
Original Assignee
JYANT TECHNOLOGIES
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JYANT TECHNOLOGIES filed Critical JYANT TECHNOLOGIES
Publication of EP2866830A1 publication Critical patent/EP2866830A1/fr
Publication of EP2866830A4 publication Critical patent/EP2866830A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
EP12880044.8A 2012-06-27 2012-06-27 Agents anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 et anti-cxcr5 pour l'inhibition de l'inflammation Withdrawn EP2866830A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/044464 WO2014003742A1 (fr) 2012-06-27 2012-06-27 Agents anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 et anti-cxcr5 pour l'inhibition de l'inflammation

Publications (2)

Publication Number Publication Date
EP2866830A1 EP2866830A1 (fr) 2015-05-06
EP2866830A4 true EP2866830A4 (fr) 2015-12-09

Family

ID=49783685

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12880044.8A Withdrawn EP2866830A4 (fr) 2012-06-27 2012-06-27 Agents anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 et anti-cxcr5 pour l'inhibition de l'inflammation

Country Status (5)

Country Link
EP (1) EP2866830A4 (fr)
JP (1) JP2015524793A (fr)
CN (2) CN112807427A (fr)
HK (1) HK1212628A1 (fr)
WO (1) WO2014003742A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3129483B1 (fr) * 2014-04-08 2018-11-21 Fraunhofer Gesellschaft zur Förderung der Angewand Polythérapie pour le traitement de maladies auto-immunes
CN105039319A (zh) * 2015-06-22 2015-11-11 浙江理工大学 用于预测乳腺癌新辅助化疗疗效的生物标记物和荧光定量免疫pcr试剂盒
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
CN107236023B (zh) * 2017-05-12 2021-05-07 苏州创澜生物科技有限公司 一种用于检测结核感染的抗原组合物及其应用
WO2019103541A1 (fr) 2017-11-24 2019-05-31 서울대학교 산학협력단 Composition anti-inflammatoire comportant une nanostructure de graphène
CN110511912B (zh) * 2018-08-30 2024-03-22 浙江煦顼技术有限公司 免疫细胞的功能调节
CN109777784B (zh) * 2019-02-22 2021-12-31 上海尚泰生物技术有限公司 一种增强向肿瘤部位迁移的嵌合抗原受体载体构建方法与应用
AU2020300544B2 (en) * 2019-07-02 2024-07-25 Astute Medical, Inc Antibodies and assays for CCL14
US11359011B2 (en) 2019-08-07 2022-06-14 Edifice Health, Inc. Treatment and prevention of cardiovascular disease
EP3960861A1 (fr) * 2020-08-31 2022-03-02 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamères ciblant cxcl9
CN114432502B (zh) * 2021-12-31 2023-02-03 中山大学附属第八医院（深圳福田） 一种负载op3-4多肽、抗cxcl9抗体的水凝胶及其制备方法与应用
AU2023243459A1 (en) * 2022-03-30 2024-11-14 Flagship Pioneering Innovations V, Inc. Cxcl-modulating compositions and methods
CN119405785A (zh) * 2025-01-07 2025-02-11 首都医科大学附属北京儿童医院 Cxcl11作为抗病毒药物的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045525A2 (fr) * 2002-11-15 2004-06-03 Morehouse School Of Medicine Anticorps anti-chimiokines et anticorps anti-recepteurs associes et utilisations de ces anticorps pour inhiber des inflammations
WO2012082494A2 (fr) * 2010-12-14 2012-06-21 Morehouse School Of Medicine Utilisation d'anticorps anti-cxcl13 et anti-cxcr5 pour le traitement ou la détection du cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU734090B2 (en) * 1996-09-10 2001-06-07 Millennium Pharmaceuticals, Inc. CXCR3 chemokine receptor, antibodies, nucleic acids, and methods of use
SI2195023T1 (en) * 2007-08-29 2018-07-31 Sanofi Humanized anti-CXCR5 antibodies, their derivatives and their uses
AU2011295902B2 (en) * 2010-09-02 2014-12-04 Vaccinex, Inc. Anti-CXCL13 antibodies and methods of using the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045525A2 (fr) * 2002-11-15 2004-06-03 Morehouse School Of Medicine Anticorps anti-chimiokines et anticorps anti-recepteurs associes et utilisations de ces anticorps pour inhiber des inflammations
WO2012082494A2 (fr) * 2010-12-14 2012-06-21 Morehouse School Of Medicine Utilisation d'anticorps anti-cxcl13 et anti-cxcr5 pour le traitement ou la détection du cancer

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
ANTHONY T. CORCORAN ET AL: "Mapping the cytokine profile of painful bladder syndrome/interstitial cystitis in human bladder and urine specimens", WORLD JOURNAL OF UROLOGY., vol. 31, no. 1, 24 March 2012 (2012-03-24), DE, pages 241 - 246, XP055246159, ISSN: 0724-4983, DOI: 10.1007/s00345-012-0852-y *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; April 2008 (2008-04-01), HARDI ROBERT ET AL: "A phase 1 open-label, single-dose, dose-escalation study of Mdx-1100, a high-affinity, neutralizing, fully human Igg1 kappa anti-CXCL10 (Ip10) monoclonal antibody, in ulcerative colitis", Database accession no. PREV200800413054 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; March 2005 (2005-03-01), GLABINSKI ANDRZEJ ET AL: "Modulation of brain immune-mediated inflammation with anti-chemokine antibodies", XP002747239, Database accession no. PREV200510320434 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; March 2005 (2005-03-01), SINGH UDAI P ET AL: "Colitis in IL-10-/- mice is mediated in part by CXCL10 production by CD4+T cells, neutrophils, and NK cells as well as CXCR3+ dendritic cells", Database accession no. PREV200510321754 *
EGESTEN ARNE ET AL: "The proinflammatory CXC-chemokines GRO-[alpha]/CXCL1 and MIG/CXCL9 are concomitantly expressed in ulcerative colitis and decrease during treatment with topical corticosteroids", INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, SPRINGER VERLAG, BERLIN, DE, vol. 22, no. 12, 1 December 2007 (2007-12-01), pages 1421 - 1427, XP036332319, ISSN: 0179-1958, [retrieved on 20071201], DOI: 10.1007/S00384-007-0370-3 *
FASEB JOURNAL, vol. 19, no. 4, Suppl. S, Part 1, March 2005 (2005-03-01), EXPERIMENTAL BIOLOGY 2005 MEETING/35TH INTERNATIONAL CONGRESS OF PHYSIOLOGICAL SCIENCES; SAN DIEGO, CA, USA; MARCH 31 -APRIL 06, 2005, pages A7 - A8, ISSN: 0892-6638 *
FASEB JOURNAL, vol. 19, no. 5, Suppl. S, Part 2, March 2005 (2005-03-01), EXPERIMENTAL BIOLOGY 2005 MEETING/35TH INTERNATIONAL CONGRESS OF PHYSIOLOGICAL SCIENCES; SAN DIEGO, CA, USA; MARCH 31 -APRIL 06, 2005, pages A1443, ISSN: 0892-6638 *
FLIER J ET AL: "Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation", JOURNAL OF PATHOLOGY, JOHN WILEY & SONS LTD, GB, vol. 194, no. 4, 1 August 2001 (2001-08-01), pages 398 - 405, XP002432876, ISSN: 0022-3417, DOI: 10.1002/1096-9896(200108)194:4<397::AID-PATH899>3.0.CO;2-S *
GASTROENTEROLOGY, vol. 134, no. 4, Suppl. 1, April 2008 (2008-04-01), DIGESTIVE DISEASE WEEK MEETING/109TH ANNUAL MEETING OF THE AMERICAN-GASTROENTEROLOGICAL-ASSOCIATION; SAN DIEGO, CA, USA; MAY 17 -22, 2008, pages A99 - A100, ISSN: 0016-5085 *
HOSOMI S ET AL: "S1705 Increased Numbers of Immature Plasma Cells in Peripheral Blood Overexpress Chemokine Receptor Cxcr3 and Cxcr4 in Ulcerative Colitis", GASTROENTEROLOGY, W.B. SAUNDERS CO, US, vol. 136, no. 5, 1 May 2009 (2009-05-01), pages A - 253, XP026111698, ISSN: 0016-5085, [retrieved on 20090501], DOI: 10.1016/S0016-5085(09)61151-3 *
JENNY L. HARDISON ET AL.: "The chemokines CXCL9 and CXCL10 promote a protective immune response but do not contribute to cardiac inflammation following infection with Trypanosoma cruzi", INFECTION AND IMMUNITY, vol. 74, no. 1, January 2006 (2006-01-01), pages 125 - 134, XP002747240 *
LACHER ET AL: "Association of a CXCL9 polymorphism with pediatric Crohn's disease", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 363, no. 3, 6 October 2007 (2007-10-06), pages 701 - 707, XP022288917, ISSN: 0006-291X, DOI: 10.1016/J.BBRC.2007.09.020 *
OGAWA T ET AL: "CXCR3 Binding Chemokine and TNFSF14 Over Expression in Bladder Urothelium of Patients With Ulcerative Interstitial Cystitis", JOURNAL OF UROLOGY, LIPPINCOTT WILLIAMS & WILKINS, BALTIMORE, MD, US, vol. 183, no. 3, 1 March 2010 (2010-03-01), pages 1206 - 1212, XP026938446, ISSN: 0022-5347, [retrieved on 20100301], DOI: 10.1016/J.JURO.2009.11.007 *
RUSCHPLER PETER ET AL: "High CXCR3 expression in synovial mast cells associated with CXCL9 and CXCL10 expression in inflammatory synovial tissues of patients with rheumatoid arthritis", ARTHRITIS RESEARCH, CURRENT SCIENCE, LONDON, GB, vol. 5, no. 5, 26 June 2003 (2003-06-26), pages R241 - R252, XP021011812, ISSN: 1465-9905, DOI: 10.1186/AR783 *
S. HOSOMI ET AL: "Increased numbers of immature plasma cells in peripheral blood specifically overexpress chemokine receptor CXCR3 and CXCR4 in patients with ulcerative colitis", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 163, no. 2, 19 November 2010 (2010-11-19), GB, pages 215 - 224, XP055509681, ISSN: 0009-9104, DOI: 10.1111/j.1365-2249.2010.04290.x *
See also references of WO2014003742A1 *
UDAI SINGH ET AL: "CXCR3 Axis: Role in Inflammatory Bowel Disease and its Therapeutic Implication", ENDOCRINE, METABOLIC & IMMUNE DISORDERS - DRUG TARGETS, vol. 7, no. 2, 1 June 2007 (2007-06-01), NL, pages 111 - 123, XP055360654, ISSN: 1871-5303, DOI: 10.2174/187153007780832109 *

Also Published As

Publication number Publication date
CN112807427A (zh) 2021-05-18
WO2014003742A1 (fr) 2014-01-03
CN104870013A (zh) 2015-08-26
HK1212628A1 (zh) 2016-06-17
JP2015524793A (ja) 2015-08-27
EP2866830A1 (fr) 2015-05-06

Similar Documents

Publication Publication Date Title
EP2866830A4 (fr) Agents anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 et anti-cxcr5 pour l&#39;inhibition de l&#39;inflammation
EP2675469A4 (fr) Compositions, dispositifs et procédés d&#39;utilisation de celles-ci dans le traitement des cancers
SI2920149T1 (sl) Spojine 3-aminocikloalkila kot zaviralci receptorja ROR-gama-t in uporaba teh spojin
IL238400A (en) Triazulophyrazines as brd4 inhibitors for use in cancer treatment
ZA201402475B (en) Self-adhesive lavatory treatment compositions
EP2678018A4 (fr) Combinaison d&#39;inhibiteurs des kinases et utilisations associées
IL253911A0 (en) Inhibitors of kynurenine-3-monooxygenase, pharmaceutical compositions, and methods of their use
IL234884A0 (en) Inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use
IL237475A0 (en) Pyrlotriazinone derivatives as pi3k inhibitors
EP2830654B8 (fr) Procédés et compositions pour traiter l&#39;inflammation
IL238177A0 (en) Methods and preparations for the treatment of cancer
IL233111A0 (en) Preparations for the treatment of inflammation
IL228719A0 (en) parp inhibitors for the treatment of cipn
EP2897689A4 (fr) Systèmes, compositions et procédés pour le traitement de l&#39;alopécie
LT2827883T (lt) Tfpi inhibitoriai ir jų panaudojimo būdai
IL236138A0 (en) Difluoro-hexahydro-cyclopentaoxazinil and difluoro-hexahydro-benzooxazinil as BACE1 inhibitors
ZA201306613B (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
EP2768331A4 (fr) Dispositifs protecteurs, composants à cet effet et leurs méthodes d&#39;utilisation
SI2617412T1 (sl) Sestavek za topično zdravljenje
GB201100651D0 (en) Treatment of inflammation
GB201218486D0 (en) Novel selective bromodomains inhibitors for the treatment of inflammation,cancer and viral infections
GB201218282D0 (en) Novel selective bromodomains inhibitors for the treatment of inflammation, cancer and viral infections
GB201218281D0 (en) Novel selective bromodomains inhibitors for the treatment of inflammation, cancer and viral infections
HK1189818A (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20141211

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 48/00 20060101ALI20151023BHEP

Ipc: A61P 29/00 20060101ALI20151023BHEP

Ipc: A61K 39/395 20060101AFI20151023BHEP

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20151106

17Q First examination report despatched

Effective date: 20170406

18D Application deemed to be withdrawn

Effective date: 20170817

18RA Request filed for re-establishment of rights before grant

Effective date: 20180626

D18D Application deemed to be withdrawn (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

R18D Application deemed to be withdrawn (corrected)

Effective date: 20200113